skip to Main Content
Abion is committed to developing innovative medicines including chemical and biological drugs and vaccines as part of our nationwide research projects. Through our endeavors thus far, we are developing an anticancer inhibiting agent ABN 401, a biobetter for multiple sclerosis, medical countermeasures for Acute Radiation Syndrome (ARS), and infectious diseases that are supported by both globally certified non-clinical and clinical processes towards eventual commercialization across international markets.

Abion’s anticancer drug candidates, based on a companion diagnostics system, are tailored to each individual patient to achieve optimal therapeutic outcomes.


An anticancer drug candidate that targets c-Met alterations in driving various cancers (lungs, stomach, etc.).

In order to enhance clinical safety and efficacy, we are developing a therapeutic c-Met targeting agent that has eliminated complications (renal toxicity) related to first generation c-Met inhibitors together with a companion diagnostic system for patient selection as well as therapeutic and resistance monitoring.


Claudin-3 , an effective biomarker that can be utilized for diagnose and treatment of various cancers (ovarian, etc.).

ABN501 is a specific therapeutic antibody targeting ovarian cancer. In comparative studies with other anticancer agents, ABN501 shows superior cancer cell death in ovarian cancer cells. Currently we are developing expression cell lines for ABN501.


A fusion protein that targets cancer cells with antitumor activity of ABN101 (Interferon-beta).

Through in vivo efficacy tests, ABN201 have superior anticancer activity against cancer cells and improves toxicity levels of existing Antibody-Drug Conjugates (ADCs) and productivity via a fusion method compare to conjugation technique.

  • Best-in-class c-Met inhibitor with companion diagnostic co-development
  • Targeting wild type and mutate c-Met that drive various cancers
  • Selected project by Korea Drug Development Fund
Indication Drug Type Development Stage Clinical Site
Discovery Non-clinical P-I P-II
c-Met driven solid tumors (lung cancer and stomach cancer) Small Molecule

* For more information on the clinical trial, please visit here.


• Predictive patient targeting and therapeutic effectiveness via companion diagnostics
• Structure design to eliminate complications of renal toxicity, which is considered the main cause of failure of first generation c-Met inhibitors
• High selectivity and specificity for c-Met

Development Goals & Strategies

• Patient selection biomarker-based companion diagnostics that utilizes a best-in-class therapy without yielding side effects or off-target effects
• In progress to achieve FDA Breakthrough Therapy designation

Patent Status

• Novell Triazolopyrazine Derivative and Use Thereof (AU, BR, CA, CN, EP, IN, JP, KR, MX, PCT, RU, US)

Abion is developing an Interferon-beta based biological drug for treatment of autoimmune diseases in the central nervous system with the goal of improving patient convenience at competitive prices.


The next generation drug for treatment of multiple sclerosis, ABN101 applies an additional glycosylation to Interferon-beta to enhance its productivity and stability.

ABN 101 will help minimize side effects and dosing frequency through improvement on solubility, pharmacokinetics and stability in comparison with marketed interferon-beta products.

  • First-line treatment for multiple sclerosis
  • Increased patient convenience and competitive pricing in response to unmet demands for effective treatment of multiple sclerosis
  • Next generation biobetter version of Interferon-beta: additional glycosylation to human Interferon-beta
  • Secured IPs from 21 countries worldwide, including U.S. and Europe
Target Drug Type Development Stage Clinical Site
Discovery Non-clinical P-I P-II
Relapsing-Remitting Multiple Sclerosis (RRMS) Biobetter


• Reduced aggregation tendency via additional glycosylation
• Improvements in solubility and stability
• Improve productivity leading to strong competitive pricing
• Increase half-life and activity which allows for less frequent dosing
• Maximize drug effects by utilizing pharmacodynamics biomarker and companion diagnostics
• Utilize various off-label markets for treatment of viral infections

Development Goals & Strategies

• Approval by European Medicines Agency (EMA)
• Extended application for treatment of viral infection and cancer

Patent Status

• Human Interferon-beta Mutein (BR, CN, EP, IN, JP, KR, PCT, US)
• Modified Interferon-beta Conjugated with Polyethylene Glycol (KR, PCT)
• Stabilized Formulations of Interferon-beta Mutant (KR, PCT)
• Immunocytokine Conjugated with Human Interferon-beta Mutein and Method for Preparing Thereof (KR, PCT)

In efforts to expand and synergize Abion’s various pipelines, we are developing ABN701 vaccine against biological agents and ABN601, a drug that protects the immune system from acute radiation syndrome.


A vaccine that protects against infection from staphylococcal enterotoxin B (SEB).

Traditional SEB vaccines have often failed due to inability to remove the toxicity of the antigen, but ABN701 as a competitive drug has been shown to be non-toxic in various animal studies. ABN701 is also a major part of a health development project currently headed by South Korea’s Ministry of Health and Welfare (MOHW).


Innovative emergency medication that can dramatically increase survival rates by protecting the immune system from radiation exposure.

ABN601 is being introduced by Abion to prevent Acute Radiation Syndrome (ARS) in patients exposed to nuclear or medical radiation accidents. As there are currently no clinically approved drugs present in South Korea, ABN601 is expected to make a significant first impact as we progress to phase I clinical trial.


Anticancer Therapies

Indication Drug Type Development Stage Clinical Site
Discovery Non-clinical P-I P-II
ABN401 c-Met mutation (lung cancer and stomach cancer) Small Molecule
ABN501 Pancarcinoma
(breast cancer, ovarian cancer, etc.)
Monoclonal Antibody
ABN201 TBD Ab-cytokine fusion protein

Multiple Sclerosis

Indication Drug Type Development Stage Clinical Site
Discovery Non-clinical P-I P-II
ABN101 Relapsing-Remitting Multiple Sclerosis (RRMS) Biobetter

Medical Countermeasures (MCM)

Indication Drug Type Development Stage Clinical Site
Discovery Non-clinical P-I P-II
ABN701 SEB (Superantigen Infection) Vaccine
ABN601 Acute Radiation Syndrome (ARS) Protein
Back To Top